MedTrace Logo

Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

NCT06308874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-12-17

No results posted yet for this study

Summary

\- Objectives: Primary objective\_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective\_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

DRUG

Amg dose administration group

Orally, Amg tablet single administration

DRUG

Amg dose administration group- Placebo

Orally, Placebo Amg tablet single administration

DRUG

Bmg dose administration group

Orally, Bmg tablet single administration

DRUG

Bmg dose administration group- Placebo

Orally, Placebo Bmg tablet single administration

Sponsors & Collaborators

  • J2H Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2023-02-17
Completion
2023-02-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06308874 on ClinicalTrials.gov